Kornimate/medical-research-clean huggingface dataset:
prevention of infection in indian neonates - phase i observational study

Conditions: Sepsis

Summary: india, with one of the world's largest populations, continues to struggle with extremely high infant and neonatal mortality rates. neonatal infection (sepsis) now accounts for 50 percent of deaths among community-born (and 20 percent of mortality among hospital-born) infants. this study is the first phase of a multi-phase project investigating interventions to prevent neonatal infection in india.

invasive bacterial infections encompass clinical diagnoses of septicemia, pneumonia, and meningitis. together, these infections are termed "neonatal sepsis" and account for over half of the newborn deaths at the district and sub-district level in india. sepsis is the most common (80-90 percent) primary diagnosis for admission in indian hospitals. phase 1 of this study is a prospective, epidemiologic study involving over 1,000 community-based and hospital populations of newborn infants. it includes identifying all infants born in study hospitals and those brought to the hospitals with suspected sepsis; obtaining blood cultures from these infants and identifying the sepsis-causing bacteria; screening of all bacterial strains isolated from blood cultures for antimicrobial resistance; collecting basic demographic, risk factor, and treatment data on each case; and developing a computer-based system/network for data management. a village-level surveillance system was put in place to identify women during their pregnancy; monitor pregnancy outcomes; and establish a mechanism for referral of all potentially septic infants to participating clinics or hospitals for evaluation, including the collection of blood cultures. potential sources of bacteria causing sepsis will be identified using molecular epidemiologic techniques. this involves matching septic infants' blood isolates with other colonizing isolates obtained from screening skin, throat, and stool cultures in the infant and skin and vaginal cultures from their mothers.

Eligibility criteria:
inclusion criteria: * age \<60 days * a diagnosis of suspected sepsis/pneumonia, based on the presence of at least one of the following symptoms at admission: poor feeding/poor sucking, decreased activity/lethargy, fever, hypothermia, cyanosis, diarrhea, abdominal distension, seizures, apneic spells, sclerema, bleeding, jaundice, tachypnea, chest wall retractions, shock. * born in one of the participating hospitals or in village inside catchment area if the screening physician does not suspect sepsis, even in the presence of one or more of the above signs, the baby should not be enrolled. exclusion criteria: • the presence of major congenital anomalies a major congenital anomaly is defined as any malformation that is felt to be life-threatening or that requires surgical intervention. if the medical officer is uncertain whether an anomaly is life-threatening, he/she should not enroll the infant.

Keywords: neonatal sepsis global network antibiotics india international maternal and child health
study of capecitabine in combination with sir-spheres in patients with advanced cancer

Conditions: Metastatic Liver Cancer

Summary: this trial is testing the safety of combining the oral chemotherapy drug capecitabine with radio-labeled microspheres injected directly into the liver.

patients with adequate liver function and performance status in whom liver-directed therapy and capecitabine would be appropriate are eligible for this clinical trial.

Eligibility criteria:
inclusion criteria: * adequate liver function * adequate performance status exclusion criteria: * significant extrahepatic disease
marijuana for cancer pain

Conditions: Neoplasms

Summary: to find out if it is safe and effective to use smoked marijuana in combination with opioids to treat cancer pain. the study will evaluate whether smoked marijuana, when used with opioids, will have an effect on pain relief, and to see if marijuana reduces the side effects of opioids, which include nausea and/or vomiting.

to take part in this study, you must have ongoing cancer pain which is currently being treated with opioids. if you meet all the eligibility criteria you will be admitted to the general clinical research center at san francisco general hospital for 9 days. the treatment consists of smoking one marijuana cigarette 3 times a day.

Eligibility criteria:
inclusion criteria * have ongoing cancer pain * be diagnosed with cancer and have at least a six month survival. * be on a stable dose of opioid medication for at least 2 weeks before enrollment. * have smoked marijuana on at least 6 occasions in their lifetime prior to enrollment. exclusion criteria you must not: * start chemotherapy, radiation or biphosphonates during the study, or have received any new intervention with any such agents within the past 4 weeks. * currently be using smoked tobacco products. * currently be in methadone treatment. * have smoked marijuana within 30 days of enrollment. * be diagnosed with diabetes mellitus. * have severe heart disease, uncontrolled hypertension, or lung disease. * currently be receiving treatment with corticosteroids. * be pregnant or breastfeeding.

Keywords: cancer pain all types of cancer except lung cancer
effect of adaptive sports after acquired physical disability

Conditions: Spinal Cord Injuries; Sports Physical Therapy

Summary: this study is a cross-sectional trial which aims to evaluate the effect of practicing a physical activity on different domains of the icf among individuals with an acquired physical disability. two different groups of individuals with a spinal cord injury will be enrolled: one composed of subjects who manage to reach the who's recommendations regarding physical activity, and the other of subjects who do not.

the present study will recruit participants based on a set of defined eligibility criteria, in adaptive sports clubs teams and in groups or associations of individuals with an acquired, and permanent, physical disability. based on the presence or absence of a regular physical activity practice undertaken by the subjects who give their consent to participate in the study, they will be divided into two groups: one where individuals regularly practice a physical activity, and one where they do not. a set of defined outcome measures (detailed in the "outcome measures"section) will be assessed in both groups. the outcomes measures will be analysed statistically, using spss software. depending on the nature of the variables (qualitative or quantitative), different tests will be performed. normality will also be verified and will determine which statistical analysis will be carried out.

Eligibility criteria:
inclusion criteria: * diagnosed non-progressive spinal cord injury * dependent on wheelchair for mobility * more than 6 months since diagnosis of spinal injury * able to understand and speak french exclusion criteria: * medical contra-indication to the testing * cognitive deficiency which limits communication
extending the time window of thrombolysis by butyphthalide up to 6 hours after onset (exit-bt)

Conditions: Stroke, Ischemic

Summary: to date, the time window of intravenous thrombolysis is limited within 4.5 hours of stroke onset. although extend study has proved that intravenous thrombolysis can be extended from 4.5 to 9 hours, but the eligible patients must be selected by ctp. thus, it is of clinical importance how to extend the time window of intravenous thrombolysis, which can benifit more patients. the current trial aims to investigate the effect of intravenous thrombolysis with tnk from 4.5 to 6 hours in ischemic stroke with help of butyphthalide, which was found to be neuroprotective.


Eligibility criteria:
inclusion criteria: * age: 18-80; * ischemic stroke confirmed by brain ct or mri * the time from onset to treatment: 4.5-6 hours * nihss≥4 * prestroke mrs≤1 * signed informed consent exclusion criteria: * prestroke mrs≥2 * planned endovascular treatment * planned intravenous thrombolysis based on wake-up or extend study criterion * any contraindiction of intravenous thrombolysis * other unsuitable conditions judged by investigator
mapping and manipulating the emotional territories of the basal ganglia in pd patients

Conditions: Parkinson's Disease

Summary: depressive symptoms of parkinson's disease (pd) patients are major predictors of their prognosis and quality of life. using subthalamic nucleus (stn) deep brain stimulation (dbs) as an antidepressant could be a promising new direction. existing methods of adjustment of dbs parameters aim at amelioration of the motor signs and therefore with inactivation of the stn motor territory only. although the dbs parameter setting is believed to influence the mental state, there is no data that correlates stimulation parameters with mental state. the investigators hypothesize that the emotional territories of the stn have distinct electrophysiological properties and that specific stimulation of these emotional territories can influence the mental state and thus treatment with emotionally-adjusted dbs can improve the psychiatric symptoms of pd. in this project, the investigators intend to map the emotional territories of the stn using neuronal (single units) responses to emotional voices and to identify the emotional spectral signature of the stn single unit activity using spectral analysis and neuronal responses to emotional voices. the investigators also intend to investigate the emotional processing of pd patients by manipulating the stimulation of the subthalamic area. the proposed study will combine neural recording, stimulation and psychological tests to shed new light on emotional processing in the basal ganglia, as well as to provide better treatment for pd emotional disorders,


Eligibility criteria:
inclusion criteria: 1. clinically definite pd treated / candidates for treatment with dbs (patients with advanced idiopathic pd who are deemed appropriate for dbs surgery). 2. patients will be included in the study irrespective of whether a diagnosis of major depression (mdd) (mild to moderate but not severe mdd) is fulfilled at baseline. patients without depression will be monitored in the study for evidence of treatment emergent depression. patients with depression will be monitored for antidepressant effects of stimulation change. 3. age 40-75 years 4. male or female. 5. competent and willing to give written informed consent exclusion criteria: 1. significant suicidal risk \[hamilton depression scale item 3 (suicide) \>2\]. 2. comorbidity with any psychotic disorder, bipolar disorder, post traumatic stress disorder (ptsd), eating disorder. 3. lifetime history of substance or alcohol dependence or of abuse in the preceding 12 months 4. significant cognitive decline, as measured by addenbrooke's cognitive examination (ace) and the frontal assessment battery (fab).

Keywords: mapping the emotional territories of the stn identifying the emotional spectral signature of the stn single unit activity manipulating emotional processing of pd patients by high and low frequency stimulation affecting long-term emotional states of the pd patients
the relationship between lower extremity selective motor control and gait in children with cerebral palsy

Conditions: Cerebral Palsy

Summary: the aim of this study is to examine the relationship between lower extremity selectivity and gait in children with cerebral palsy. 32 volunteer children with cp between the ages of 5-20 will participate in the study. the selective control assessment of the lower extremity (scale) questionnaire will be used to assess lower extremity selectivity, and the edinburgh observational gait scale will be used to assess gait. both assessments are observational.


Eligibility criteria:
inclusion criteria: * between the ages of 5-20 * diagnosed with cp exclusion criteria: * medical complications that limit participation in assessments (for example, severe visual impairment) * lower extremity surgery or botox surgery in the last 6 months * mental problems that cannot understand the commands given
biomarker analysis of solid cancers such as gastrointestinal cancer

Conditions: Sarcoma

Summary: to prospectively collect ascites, pleural fluid, circulating tumor cells and derived primary cultures from metastatic cancer patients. the specimens will be analyzed using dna/rna/proteomic approaches.


Eligibility criteria:
inclusion criteria: 1. patients with histologically confirmed gastrointestinal, genitourinary, sarcoma, rare cancer 2. written informed consent 3. body fluid derived from cancer, available for drainage and collection exclusion criteria: * patients who do not give informed consent form for research use of biomaterials/biospecimens

Keywords: gastrointestinal genitourinary rare cancer
an evaluation of the ability to train established glaucoma patients who have difficulty in drop instillation

Conditions: Glaucoma; Ocular Hypertension

Summary: this is a prospective, observational, single-center study. patients with at least 3 months of experience using topical medications for glaucoma and who state that they administer their own eye drops will be recruited. subjects will be videotaped instilling a sterile artificial eye drop, will be identified at the time of a regularly scheduled exam. if the patient can get a drop onto the eye and also not touch their lids or ocular surface with the eye drop bottle, the subject will be thanked but not enrolled. all other patients who agree to participate will be enrolled. upon completion of videotaped instillation of an eye drop, each enrolled patient will be shown a video demonstrating an instillation technique and will be given an instructional handout highlighting a proper drop instillation technique. if necessary, an instillation technique will be demonstrated to them by an investigator or trained personnel. a patient will be identified as properly instilling a drop if they satisfy the following criteia: they are able to instill one (and only one) drop to the ocular surface or lower fornix without allowing the bottle touch the adnexa, eyelid, eye lashes or eye. all patients routinely return between 3 and 6 months. at this regularly scheduled visit,the investigator or trained personnel would direct the patient to instill an eye drop into the study eye.additionally, the short glaucoma self-efficacy questionnaire will be re-administered. all of the video-recordings of participants' eye drop instillation techniques will be reviewed and assessed using a standard checklist. their ability to administer an eye drop after training will be compared to baseline.


Eligibility criteria:
inclusion criteria: * patients aged 18 years or older * patients currently using topical ocular antihypertensive medications at the time of enrollment in at least one eye, and who have been using these drops consistently for a period of at least three months prior to enrollment. * patients with primary open angle glaucoma, pigmentary glaucoma, exfoliation glaucoma, ocular hypertension, normal-tension glaucoma, neovascular glaucoma, uveitic glaucoma and chronic narrow angle glaucoma. * patients can be enrolled even if they have co-existing morbidities such as parkinson's disease or arthritis exclusion criteria: * patients who do not instill their own eye drops * patients who are not expected to still be using topical antihypertensive medications at the time of study follow-up * patients with no light perception vision * patients with a history of adverse reaction to artificial tears or any component of artificial tears * patients who have a typical follow-up period of greater than 6 months * patients who have not completed a humphrey visual field c24-2 or c10-2 within 7 months of enrollment or study exit.

Keywords: glaucoma eye drop eye drop technique training instilling eye drops
improving spinal cord injury rehabilitation interventions by retraining the brain with stimulation

Conditions: Spinal Cord Injury

Summary: the purpose of this study is to investigate whether combining a noninvasive method of brain stimulation, called transcranial direct current stimulation (tdcs), enhances the effect of training of the affected upper limbs in patients with incomplete spinal cord injury.

the long-term objective of this study is to optimize the rehabilitative potential in spinal cord injury (sci) by maximally harnessing the potential available for functional neural plasticity. sci is an important cause of serious, long-term disability in young adults. this fact, further complicated by rising disability-related costs, makes sci a significant economic and social burden. upper limb dysfunction is one of the most prevalent and debilitating impairments. more than 75% of patients with quadriplegia (paralysis of all 4 limbs following spinal cord injury in neck and upper back) prioritize return of upper limb function over any other lost function. alleviating deficits of the upper limb may represent a cost-effective stategy to reducing the burden of sci. although various exercise programs and neuromuscular stimulation methods have been employed to mitigate functional impairments of the arm and hand, success of these modalities is still debated. evidence for efficacy of rehabilitation is inconclusive as outcomes are variable, confounded by methodological issues, and have shown poor generalizability. it is now speculated that limited succcess of rehabilitation emerges from inability of current methods to adequately harness the potential for significant neuroplasticity available in sci. even though the site of damage in sci does not involve the brain, the neural networks in the brain that control movement of the arm and hand are markedly affected. these regions lose their territory that the investigators argue could hamper effects of upper limb therapy. the investigators objective is to directly modulate adaptive plasticity in these regions of the brain to enhance function of the upper limb in isci. the investigators central hypothesis is that noninvasive brain stimulation, called transcranial direct current stimulation (tdcs), when delivered concurrently with rehabilitation will generate synergistic functional advantage. adaptive plasticty would be obeserved as changes in structure of pathways emerging from the brain and the individual's function.

Eligibility criteria:
inclusion criteria: * diagnosed with incomplete spinal cord injury (isci) that occurred at least 6 months ago exclusion criteria: * history of epilepsy in a first degree relative * use of anticonvulsants * pregnant * implanted pumps, shunts, or neurostimulators * neurologic condition affecting sensorimotor systems * brain tumor * dementia * substance abuse * stroke * damaged skin on the scalp * concurrent upper limb rehabilitation

Keywords: incomplete spinal cord injury quadriplegia tetraplegia sci spinal cord disease spinal cord injury isci transcranial direct current stimulation tdcs sci recovery brain stimulation rehabilitation
raloxifene for prevention of bone loss in postmenopausal patients receiving chronic corticosteroid therapy

Conditions: Osteoporosis

Summary: this study is a double-blind placebo-controlled trial evaluating the efficacy of raloxifene in the prevention of bone mineral density loss in patients receiving long term corticosteroids.


Eligibility criteria:
inclusion criteria: 1. postmenopausal patients with various chronic rheumatic diseases receiving chronic steroid therapy. 2. stable disease for at least 6 months prior to study with a stable dose of steroid (prednisone \<= 10 mg/day or equivalent). 3. baseline bone mineral density (bmd) of the lumbar spine t score \< -1.0. exclusion criteria: 1. patients with a history of thromboembolism. 2. patients with positive antiphospholipid antibodies. 3. history of allergic reactions or intolerance to raloxifene or other serms. 4. patients receiving bisphosphonates, parathyroid hormone, serms, anticonvulsants or anti-cytokine therapies within 6 months prior to study entry. 5. patients with known bone disorders such as osteomalacia, renal osteodystrophy, and hyperparathyroidism. 6. patients with abnormal uterine bleeding of unknown etiology. 7. patients with serum creatinine level of \>= 200 umol/l.

Keywords: raloxifene estrogen receptor modulation osteoporosis steroid steroids
efficacy and safety of l-pantoprazole sodium injection to treat upper gastrointestinal ulcer bleeding

Conditions: Bleeding Gastric Ulcer; Bleeding Duodenal Ulcer

Summary: the purpose of this study is to evaluate the safety and efficacy of l- pantoprazole sodium to treat upper gastrointestinal ulcer bleeding.


Eligibility criteria:
inclusion criteria: 1. age: 18-65 years, gender:both. 2. patients whose forrest classification were in ⅰ b-ⅱ c were diagnosed with non-variceal duodenal and / or gastric ulcer bleeding by endoscopy within 24 hours and patients manifested vomiting and / or black stools and other symptoms of upper gastrointestinal bleeding. 3. patients were diagnosed with upper gastrointestinal bleeding mild to moderate; 4. informed consent granted. 5. patients agreed to take medicine and assess. exclusion criteria: 1. patients were diagnosed with upper gastrointestinal bleeding by endoscopy caused by esophageal varices and portal hypertensive gastropathy, mallory-weiss syndrome, dieulafoy disease. 2. pregnant women or breastfeeding women. 3. patients who had undergone surgery because of ulcer complications or gastrectomy, gastrointestinal anastomosis within 30 days before the trial. 4. patients were diagnosed with gastrinoma or gastric malignancy. 5. patients had other associated complications, which may affect the efficacy. 6. patients who like alcohol abuse, drug addicts or others which are not suitable for drug trials. 7. patients who were allergic to any ingredient of any ppi and allergies. 8. patients diagnosed with small vessel spurting who had to undergo endoscopic hemostasis or surgery or severe gastrointestinal bleeding. 9. patients suffering from serious heart, brain, lung, liver, kidney disease or severe hypertension. 10. patients who had coagulopathy, whose pt wasmore three seconds than normal controls, whose aptt\> 1.5 times the upper limit of normal or low-dose heparin treatment. 11. patients whose systolic blood pressure less than 90mmhg or lower \> 30mmhg than the baseline systolic blood pressure, pulse pressure less than 20mmhg, hematocrit less than 20%. 12. patients who participated in other clinical trials within three months before this trial. 13. patients who need to use other drugs which may affect the trial during the trial or a week before the trial. 14. patients who were considered unsuitable for selected candidates.